IPO - Profile

Summary

We are a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. Our lead investigational product is the LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. We believe that by using the same cells that promote tissue repair, organ maintenance, and immune system function, we can develop safe and effective therapies for some of the most difficult disorders associated with the aging process.

We are currently sponsoring Phase 1 and More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$10.00 2,660,000 Positive High 104.76%

Offering Team

  • Legal counsel
  • Nelson Mullins Riley & Scarborough LLP
  • Auditors

Deal Highlights

Deal Tracker

IPO Dates

Filing 11 Feb, 2021

Offer 12 Feb, 2021

Look Ahead

Lock Up Expiry Aug 12, 2021

IPO Terms

Offer Price $10.00
Offer Size 2M

Market Sentiments

Stock Price